Targeting the correct HDAC(s) to treat cognitive disorders

被引:320
作者
Fischer, Andre [1 ]
Sananbenesi, Farahnaz [1 ]
Mungenast, Alison [2 ,3 ,4 ]
Tsai, Li-Huei [2 ,3 ,4 ]
机构
[1] European Neurosci Inst, Lab Aging & Cognit Dis, D-37077 Gottingen, Germany
[2] MIT, Picower Inst Learning & Memory, Cambridge, MA 02139 USA
[3] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA
[4] Broad Inst, Stanley Ctr Psychiat Res, Cambridge, MA 02139 USA
关键词
HISTONE DEACETYLASE INHIBITORS; RUBINSTEIN-TAYBI-SYNDROME; NUCLEAR RECEPTOR TLX; GENE-EXPRESSION; SYNAPTIC PLASTICITY; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; REGULATES MEMORY; BIPOLAR DISORDER; BROAD-SPECTRUM;
D O I
10.1016/j.tips.2010.09.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Changes in gene expression in the brain may underlie cognitive deficits inherent to normal aging and neurodegenerative disease. However, the mechanisms underlying pathological alterations in the brain transcriptome are incompletely understood. Epigenetic mechanisms such as DNA methylation and histone acetylation have been shown to be important for memory processes in the adult brain. There is accumulating evidence that altered chromatin plasticity and histone acetylation are also involved in cognitive aging, neurodegeneration, and neuropsychiatric diseases. Inhibitors of histone deacetylase (HDAC) exhibit neuroprotective and neuroregenerative properties in animal models of various brain diseases. As such, targeting of HDACs seems to be a promising therapeutic strategy. In this review, we discuss the specific roles of each HDAC protein and the possible function of distinct histone modifications. We hope that this knowledge will aid in the development of diagnostic tools and in designing more potent and specific treatment for neurological disorders targeting selective HDAC proteins.
引用
收藏
页码:605 / 617
页数:13
相关论文
共 163 条
  • [11] Gene expression changes in the course of normal brain aging are sexually dimorphic
    Berchtold, Nicole C.
    Cribbs, David H.
    Coleman, Paul D.
    Rogers, Joseph
    Head, Elizabeth
    Kim, Ronald
    Beach, Tom
    Miller, Carol
    Troncoso, Juan
    Trojanowski, John Q.
    Zielke, H. Ronald
    Cotman, Carl W.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (40) : 15605 - 15610
  • [12] An operational definition of epigenetics
    Berger, Shelley L.
    Kouzarides, Tony
    Shiekhattar, Ramin
    Shilatifard, Ali
    [J]. GENES & DEVELOPMENT, 2009, 23 (07) : 781 - 783
  • [13] Genome-wide association studies in Alzheimer's disease
    Bertram, Lars
    Tanzi, Rudolph E.
    [J]. HUMAN MOLECULAR GENETICS, 2009, 18 : R137 - R145
  • [14] Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control
    Bhaskara, Srividya
    Chyla, Brenda J.
    Amann, Joseph M.
    Knutson, Sarah K.
    Cortez, David
    Sun, Zu-Wen
    Hiebert, Scott W.
    [J]. MOLECULAR CELL, 2008, 30 (01) : 61 - 72
  • [15] Perceptions of epigenetics
    Bird, Adrian
    [J]. NATURE, 2007, 447 (7143) : 396 - 398
  • [16] Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death
    Bolger, TA
    Yao, TP
    [J]. JOURNAL OF NEUROSCIENCE, 2005, 25 (41) : 9544 - 9553
  • [17] Distribution of histone deacetylases 1-11 in the rat brain
    Broide, Ron S.
    Redwine, Jeff M.
    Aftahi, Najla
    Young, Warren
    Bloom, Floyd E.
    Winrow, Christopher J.
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2007, 31 (01) : 47 - 58
  • [18] A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia.
    Buchanan, RW
    Davis, M
    Goff, D
    Green, MF
    Keefe, RSE
    Leon, AC
    Nuechterlein, KH
    Laughren, T
    Levin, R
    Stover, E
    Fenton, W
    Marder, SR
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (01) : 5 - 19
  • [19] BUCHANAN RW, 2010, SCHIZOPHR B
  • [20] Histone deacetylase inhibitors as therapeutics for polyglutamine disorders
    Butler, Rachel
    Bates, Gillian P.
    [J]. NATURE REVIEWS NEUROSCIENCE, 2006, 7 (10) : 784 - 796